Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

An unusual cause of multiple cerebral hemorrhages: drotrecogin alpha (activated protein C).

Algin O, Ceylan G, Kilic E.

AJNR Am J Neuroradiol. 2011 May;32(5):E85-6. doi: 10.3174/ajnr.A2097.

2.

An updated meta-analysis to understand the variable efficacy of drotrecogin alfa (activated) in severe sepsis and septic shock.

Lai PS, Matteau A, Iddriss A, Hawes JC, Ranieri V, Thompson BT.

Minerva Anestesiol. 2013 Jan;79(1):33-43. Review.

3.

Drotrecogin alfa (activated) in an infant with gram-negative septic shock.

Sajan I, Da-Silva SS, Dellinger RP.

J Intensive Care Med. 2004 Jan-Feb;19(1):51-5.

PMID:
15035755
4.

[Re-administration of drotrecogin alfa activated in a patient with episodes of severe sepsis].

Verdú MT, Sánchez OJ.

Rev Esp Anestesiol Reanim. 2007 Dec;54(10):637-8. Spanish. No abstract available.

PMID:
18201006
5.

Corticosteroids and human recombinant activated protein C for septic shock.

Colin G, Annane D.

Clin Chest Med. 2008 Dec;29(4):705-12, x. doi: 10.1016/j.ccm.2008.06.009. Review.

PMID:
18954704
6.

Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock.

Dhainaut JF, Antonelli M, Wright P, Desachy A, Reignier J, Lavoue S, Charpentier J, Belger M, Cobas-Meyer M, Maier C, Mignini MA, Janes J.

Intensive Care Med. 2009 Jul;35(7):1187-95. doi: 10.1007/s00134-009-1436-1. Erratum in: Intensive Care Med. 2009 Jul;35(7):1319-21.

PMID:
19263034
7.

Venous thromboembolism in critically ill patients. Observations from a randomized trial in sepsis.

Shorr AF, Williams MD.

Thromb Haemost. 2009 Jan;101(1):139-44.

PMID:
19132200
8.

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.

Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent JL.

Crit Care. 2003 Apr;7(2):155-63. Review.

9.

Efficacy and safety of recombinant human activated protein C for severe sepsis.

Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group..

N Engl J Med. 2001 Mar 8;344(10):699-709.

10.

New additions to the intensive care armamentarium.

Rice TW, Bernard GR.

Drugs Today (Barc). 2004 Feb;40(2):157-70. Review.

PMID:
15045037
11.

Drotrecogin alfa (activated) for the treatment of severe sepsis and septic shock.

Rice TW, Bernard GR.

Am J Med Sci. 2004 Oct;328(4):205-14. Review.

PMID:
15486535
12.

Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.

De Backer D.

Drug Saf. 2007;30(11):995-1010. Review.

PMID:
17973539
13.

Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.

Barton P, Kalil AC, Nadel S, Goldstein B, Okhuysen-Cawley R, Brilli RJ, Takano JS, Martin LD, Quint P, Yeh TS, Dalton HJ, Gessouron MR, Brown KE, Betts H, Levin M, Macias WL, Small DS, Wyss VL, Bates BM, Utterback BG, Giroir BP.

Pediatrics. 2004 Jan;113(1 Pt 1):7-17.

PMID:
14702440
14.

Influence of drotrecogin alpha (activated) infusion on the variation of Bax/Bcl-2 and Bax/Bcl-xl ratios in circulating mononuclear cells: a cohort study in septic shock patients.

Bilbault P, Lavaux T, Launoy A, Gaub MP, Meyer N, Oudet P, Pottecher T, Jaeger A, Schneider F.

Crit Care Med. 2007 Jan;35(1):69-75.

PMID:
17133181
16.

Activated protein C for sepsis.

Toussaint S, Gerlach H.

N Engl J Med. 2009 Dec 31;361(27):2646-52. doi: 10.1056/NEJMct0808063. Review. No abstract available.

PMID:
20042756
17.

Treatment of septic shock and use of drotrecogin alfa (activated) in children.

Marraro GA.

Expert Rev Anti Infect Ther. 2009 Sep;7(7):769-72. doi: 10.1586/eri.09.65. No abstract available.

PMID:
19735218
18.
19.

Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.

McCoy C, Matthews SJ.

Clin Ther. 2003 Feb;25(2):396-421. Review.

PMID:
12749504
20.

Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis.

Kanji S, Devlin JW, Piekos KA, Racine E.

Pharmacotherapy. 2001 Nov;21(11):1389-402. Review.

PMID:
11714212
Items per page

Supplemental Content

Support Center